Brain tumour immunology and therapy group

Main content


  • PhD in Molecular Biosciences (2012) at Department of Molecular Biosciences, University of Oslo, Norway
  • Master in Bio-and Food Technology (2007) at Department of Bio-and food technology, Lund University, Sweden
  • Bachelor in Biotechnology (1997-2001) at Biotechnology Discipline, Khulna University, Bangladesh

Work Experience:

  • Researcher (From 2015- ) at Department of Biomedicine, University of Bergen, Norway
  • Post-doctoral fellow (2012-2015) at Department of Biomedicine, University of Bergen, Norway
  • Teaching and Research Assistant (2002-2005) at Department of Biotechnology and Genetic Engineering, University of Development Alternative, Bangladesh


  • Identifying novel drugs to sensitize glioblastoma (GBM) cells to Temozolomide chemotherapy: Approximately 50% of the glioblastoma (GBM) patients with unmethylated MGMT promoter gain marginal benefit from Temozolomide chemotherapy.  My project is focused on investigating the novel drugs combinations that may potentiate the efficacy of Temozolomide chemotherapy and/or radiotherapy against GBM.
  • Bioinformatic analysis of sequencing data: This project aims to identify immune and cancer related genes that may inform disease associations or impact prognosis, respectively. I use large population databases including sequencing data deposited in The Cancer Genome Atlas project (TCGA), 1000 genomes as well as sequencing data from our local biobanks (patients and healthy population).
  • Characterization of epigenetic changes in immune cell subsets as a result of prior human cytomegalovirus infection in n brain tumor patients.


Publications List: